UnitedHealthcare
Community Plan

Prior Authorization Request Form
Fax Back To: (866) 940-7328
Phone: (800) 310-6826

Specialty Medication Prior Authorization Cover Sheet

(This cover sheet should be submitted along with a Pharmacy Prior Authorization Medication Fax Request Form. Please refer to www.uhcprovider.com for medication fax request forms.)

Patient Information

Patient's Name:

Insurance ID: Date of Birth: Height: Weight:

Address: Apartment #:

City: State: Zip Code:

Phone Number: Alternate Phone: Sex: ☐ Male ☐ Female

Provider Information

Provider's Name: Provider ID Number:

Address: City: State: Zip Code:

Suite Number: Building Number:

Phone Number: Fax number:

Provider's Specialty:

Medication Information

Medication: Quantity: ICD10 Code:

Directions: Diagnosis: Refills:

Physician Signature**: Initial here if DAW:

Physician Signature**: By signing above, the physician is providing the specialty pharmacy with a prescription that can be used to facilitate the dispensing and/or coordination of delivery for the requested medication.

Medication Instructions

Has the patient been instructed on how to **Self-Administer**? ☐ Yes ☐ No

Is this medication a **New Start**? ☐ Yes ☐ No

If continuation please provide the following: Initiation Date: / / Date of Last Dose: / /

Is there documentation of positive clinical response to current therapy? ☐ Yes ☐ No

****Please attach any pertinent clinical information that would pertain to support stated diagnosis. Additional clinical information may be needed depending on your patients plan, including medication(s) previously tried and failed.**

Delivery Instructions

Note: Delivery coordination requires a "**Physician Signature**" above and complete "**Provider Information**" and "**Patient Information**"

Note: All necessary ancillary supplies are provided free of charge to the patient at the time of delivery

Ship to: Physician's Office ☐ Patient's Address ☐ Date medication is needed: / /

Medication Administered: Home Health ☐ Self-Administered ☐ LTC ☐ Physician's Office ☐

This electronic fax transmission, including any attachments contains information for or from UnitedHealthcare that may be confidential and/or privileged. The information contained in this facsimile is intended to be for the sole use of the individual(s) or entity named above. If you are not the intended recipient, be aware that any disclosure, copying, distribution or use of the contents of this information is strictly prohibited by law and will be vigorously prosecuted. If you have received this electronic fax transmission in error, please notify the sender immediately and destroy all electronic hard copies of the communications including attachments

UnitedHealthcare Community Plan

Votrient - Washington

PRIOR AUTHORIZATION REQUEST FORM

Please complete this entire form and fax it to: **866-940-7328**. If you have questions, please call **800-310-6826.**

This form contains multiple pages. Please complete all pages to avoid a delay in our decision.

Allow at least 24 hours for review.

Section A – Member Information		
First Name:	Last Name:	Member ID:
Address:		
City:	State:	ZIP Code:
Phone:	DOB:	Allergies:
Primary Insurance Information:		

Is the requested medication □ New or □ Continuation of Therapy? If continuation, list start date: ________________

Is this patient currently hospitalized? □ Yes □ No If recently discharged, list discharge date: _________________

Section B - Provider Information				
First Name:		Last Name: M.D./D.O.		
Address:		City:	State:	ZIP code:
Phone:	Fax:	NPI #:	Specialty:	
Office Contact Name / Fax attention to:				

Section C - Medical Information	
Medication:	**Strength:**
Directions for use:	**Quantity:**
Diagnosis (Please be specific & provide as much information as possible)**:**	**ICD-10 CODE:**

Is this member pregnant? □ Yes □ No If yes, what is this member's due date? _______________

Section D – Previous Medication Trials

Medications	Strength	Directions	Dates of Therapy	Reason for failure / discontinuation

Section E – Additional information and Explanation of why preferred medications would not meet the patient's needs:
Please refer to the patient's PDL for a list of preferred alternatives

UnitedHealthcare Community Plan

Votrient - Washington

PRIOR AUTHORIZATION REQUEST FORM

Member First name:	Member Last name:	Member DOB:

Clinical and Drug Specific Information

ALL REQUESTS	
□ **Yes** □ **No**	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Renal Cell Carcinoma (RCC) □ Soft Tissue Sarcoma (STS) □ Thyroid Carcinoma □ Uterine Sarcoma □ Ovarian Cancer
□ **Yes** □ **No**	**Is Votrient being requested for a use supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium?** *If yes, list supported use:*
RENAL CELL CARCINOMA (RCC)	
□ **Yes** □ **No**	**Does the patient meet one of the following criteria?** *(If yes, check which applies)* □ Disease is relapsed □ Stage IV disease
SOFT TISSUE SARCOMA (STS)	
□ **Yes** □ **No**	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Angiosarcoma □ Pleomorphic Rhabdomyosarcoma □ Retroperitoneal/Intra-Abdominal of Non-Liposarcoma Origin □ Soft Tissue Sarcoma of the Extremity/Superficial Trunk or Head/Neck, of Non-Liposarcoma Origin □ Progressive Gastrointestinal Stromal Tumors (GIST)
□ **Yes** □ **No**	**Is the patient's disease unresectable or progressive?**
□ **Yes** □ **No**	**Is the patient's disease synchronous stage IV or recurrent and has disseminated metastases?**
□ **Yes** □ **No**	**Does the patient have a history of failure, contraindication, or intolerance to any of the following?** *(If yes, check which applies and complete Section D above)* □ Gleevec (imatinib) □ Sutent (sunitinib) □ Stivarga (regorafenib)
THYROID CARCINOMA	
□ **Yes** □ **No**	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Follicular carcinoma □ Hürthle cell carcinoma □ Papillary carcinoma □ Medullary Carcinoma
□ **Yes** □ **No**	**Does the patient meet one of the following criteria?** *(If yes, check which applies)* □ Unresectable Locoregional Recurrent Disease □ Persistent Disease □ Metastatic Disease
□ **Yes** □ **No**	**Does the patient meet one of the following criteria?** *(If yes, check which applies)* □ Symptomatic Disease □ Progressive Disease
□ **Yes** □ **No**	**Is the patient's disease refractory to radioactive iodine treatment?**
□ **Yes** □ **No**	**Does the patient have a history of failure, contraindication, or intolerance to one of the following?** *(If yes, check which applies and complete Section D above)* □ Caprelsa (vandetanib) □ Cometriq (cabozantinib)

UnitedHealthcare Community Plan

Votrient - Washington

PRIOR AUTHORIZATION REQUEST FORM

OVARIAN CANCER	
□ Yes □ No	**Does the patient have one of the following diagnoses?** *(If yes, check which applies)* □ Epithelial Ovarian Cancer □ Fallopian Tube Cancer □ Primary Peritoneal Cancer
□ Yes □ No	**Does the patient meet both of the following criteria: Disease is stage II to IV AND patient is in complete remission following primary treatment?**
□ Yes □ No	**Does the patient meet one of the following criteria?** *(If yes, check which applies)* □ Disease is persistent □ Disease is recurrent
□ Yes □ No	**Will Votrient be used as a single agent?**
□ Yes □ No	**Does the patient meet both of the following criteria?** *(If yes, check which applies)* □ Disease is platinum resistant □ Votrient will be used in combination with weekly paclitaxel
CONTINUATION OF THERAPY	
□ Yes □ No	**Does the patient show evidence of progressive disease while on Votrient therapy?**
□ Yes □ No	**Does the patient have a documented positive clinical response to Votrient therapy?** *If yes, list response:*

Physician Signature: ____ **Date:** ___________________

Confidentiality Notice: This transmission contains confidential information belonging to the sender and UnitedHealthcare. This information is intended only for the use of UnitedHealthcare. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action involving the contents of this document is prohibited. If you have received this telecopy in error, please notify the sender immediately.